Defects in
Early reports described infant boys with bloody diarrhea, who subsequently manifested eczema on the face and extremities, as well as undue susceptibility to pyogenic and opportunistic infections.'.' Later reports describe severely thrombocytopenic patients with typically less than 10% of the normal number of circulating platelets; their platelets are also small with effective average diameter of 1.82 2 .l2 pm compared with normal platelet diameter of 2.3 i: .l2 pm. 6 The primary cause of the profound thrombocytopenia appears to be accelerated platelet destruction (''destructive thrombocytopenia"). The number and morphology of megakaryocytes in WAS bone marrow (BM) are normal, suggesting that thrombocytopoiesis is Normal donor platelets transfused in WAS patients have a normal lifespan, whereas the lifespan of transfused autologous platelets is significantly ~hortened.~.~ These findings strongly suggest that the loss of circulating WAS platelets occurs because the platelets are intrinsically abnormal.
Accelerated platelet destruction in the WAS explains why platelet count can be elevated toward normal by splenectomy, an important therapeutic modality for some WAS patients."'." In addition, the platelet size also increases toward normal after splenectomy,10," suggesting that circulation of platelets through the spleen contributes to the reduction of size.6 Several functional defects measured by in vitro assays have been reported in WAS platelet^^.'^"^; however, these data are difficult to interpret because the small size and low numbers of platelets complicate comparisons with values from normal subjects."
Whereas thrombocytopenia with small platelets is apparent at birth in WAS patients and is consistently expressed, the immune defects appear later and are variable and progressive"; they include eczema, inability to generate antipolysacBlood, Vol 87, No 7 (April l), 1996: pp 2621-2631 charide antibodies, and susceptibility to pyogenic and opportunistic infections and in some cases to transient autoimmune disease.16"9 T-lymphocyte function and number decrease with age with lymphopenia apparent after age 6." Older patients have increased incidence of malignancies, particularly non-Hodgkin's lymphomas.21-2' BM transplantation (BMT) corrects the disease by engraftment of normal stem cells, a treatment that has been successful in this disease, particularly with HLA-identical donorhecipient pair^.^^.^'
Defective immune responses are noted in WAS patients. This is particularly true of their response to polysaccharide antigens to which they do not make antibodies, as demonstrated initially by low or absent titers of isohemagglutinins.*' The patient lymphocytes show normal response to nonspecific mitogens such as phytohemagglutinin, near-normal response to some protein aatigens, but deficient response to others as shown with the bacteriophage $X174.16~18~2"~2' Decreased proliferative response to the mitogen periodate has also been In a transplantation case that achieved partial chimerism with engraftment of only T cells, the immune defects, including eczema and antibody generation to polysaccharide, were ~orrected,'~ suggesting that the deficient antibody production in this disease is at least partially caused by malfunction of T cells.
In contrast to the deficient levels of isohemagglutinins, the sera from WAS patients have low levels of IgM, normal levels of IgG, and increased levels of IgA, IgD, and IgE,17,".34 a pattern that suggests robust maturatiodactivation of B cells. Activation and expansion of B cells is also suggested by the notable incidence of B-cell lymphomas among older WAS patients.'' It has been noted that areas in lymph nodes and spleen of WAS patients are depleted of T cells, and that B cells are numerous as immunoblasts and plasma cells.1h3' One study of a 4-year-old WAS patient identified an additional abnormality in the poorly developed follicles in the spleen and lymph node and the absence of germinal centers, suggesting severe deficiency of immature B cells. 35 It is not known whether intrinsic defects exist in the WAS in cells other than platelets and lymphocytes. At the clinical level, infections are frequent. However, with the exception of a report of deficient chemotactic response,20 functional properties of neutrophils including motility, phagocytosis, and release of lysosomal enzymes were found to be norfound to be n~rmal,'~'~ except for a report of deficient chemotactic response of mononuclear leukocytes." mal,13,1h.zx Similarly, functions of WAS macrophages were Obligate female heterozygous carriers of the WAS are normal hematologically. Study of these individuals showed that the X-chromosome bearing the defective gene is preferentially inactivated ("nonrandom inactivation") in their T and B lymphocytes, platelets, monocytes, granulocyte^,^^^^" myeloid progenitor cells:' and CD34+ progenitor cells,J2 but not in erythrocytes of the single female carrier studied.'x In normal females, one of each pair of X chromosomes is randomly inactivated early in development, and most tissues are mosaics with approximately half the cells having maternally derived X as the active X and half having paternally derived X as the active X.4' In instances where one X chromosome carries a gene defect that is detrimental to the survival of a particular cell lineage, all cells of the affected lineage have the nonmutant X as the active X.38,'9, 44 Thus, nonrandom X-chromosome inactivation in myeloid progenitor cells and CD34+ cells of obligate WAS carriers suggests that WASP has a critical role in pivotal progenitor cells and could explain the nonrandom inactivation in multiple blood cell lineages.
Although the disease is in many cases severe, prognosis in the WAS has improved substantially since the uniformly fatal early cases through BMT, where possible, and other interventions including splenectomy, large doses of immune globulin by the intravenous route, antibiotics, and other modes of supportive are.",*^^" Diagnosis of WAS has always been difficult. A 1994 review of clinical and laboratory data on 122 patients" found that the classic triad of thrombocytopenia, immunodeficiency, and eczema was usually absent at initial evaluation. The investigators concluded that diagnosis must rest on a compatible constellation of findings such as small size of platelets, which is relatively specific for the abnormal T-or B-cell function, and/or a compatible pattern of maternal X-chromosome i n a c t i~a t i o n .~~.~~.~' Because of the breadth of disease manifestations, clinical management of individual WAS patients would be facilitated by understanding the relationships of the genomic defects, cellular defects, and clinical features of this disease, a goal that may be attainable now that the primary defective gene has been identified.
DNA DEFECTS
The primary genetic lesion in the WAS. The WAS is a monogenic defect, which maps to Xp I 1.22. At first the gene was localized to a region bounded by the markers DXS255 and TIMP,4X"52 and these highly polymorphic DNA probes proved useful in prenatal diagnosis.4y~.50~5'~54 By positional cloning, the gene (WASP) was isolated and found to encode a novel protein whose derived amino acid sequence is composed of S02 residues3 The map location was subsequently refined.54 The gene contains 12 exonss5 spanning -9 kb.' Genomic DNAs from 77 families have been sequenced, revealing primary defects in WASP in all cases3~8~55-5y @re-sented below).
X-linked thrombocytopenia (XLT).
A number of young males were described with thrombocytopenia and small platelets with absent or minimal immunologic defects (Xlinked thrombocytopenia; XLT) (eg, see refs 60 and 61 arm of the disease.
WASP A NOVEL PROTEIN
Analysis of the deduced WASP sequence failed to reveal homology to known proteins or protein regions, and thus the long-sought identification of the defective X-encoded WAS product did not by itself substantially increase understanding of the disease. A noteworthy feature of the sequence is the absence of a signal sequence, strongly indicating that WASP is an intracellular protein. Proline residues, which can have a profound effect on structure, are prevalent (91 of 502 amino acids). Many prolines are clustered: (Pro)4 appears three times and (Pro)s, (Pro)fi, (Pro)7, and (Pro),, appear once. Homopolymeric proline stretches introduced into recombinant constructs can function in transcriptional activation.% A candidate nuclear localization sequence was identified,' also supporting the view that WASP may function in the nucleus. It has been suggested that WASP may contain proline-rich Src homology-3 (SH3) binding domains' that can mediate protein-protein interaction^.^^.^^ However, because proline content is so high, rigorous work will be needed to distinguish physiological SH3 interactions from nonspecific SH3-like binding.
Homopolymeric proline stretches have a different function in other proteins, eg, in yeast cytoskeletal proteins, in which they mediate interaction with actin and profilinfi9; this putative function for WASP regions would be consistent with the cytoskeletal defects found in WAS cells (discussed below). WASP also has regions of dense negative charge, a feature characteristic of protein domains that function as low-affinityhigh-capacity Ca2+ binding domains, eg, in calsequestrir~.~') Defects of Ca2+ regulation could explain the depletion of Ca2+-dependent protease (calpain) in WAS platelets (discussed below).
WASP mRNA is expressed in thymus and in HEL megakaryocyte-like erythroleukemia cells, but not in a variety of nonhematopoietic cells including muscle, liver, stomach, pancreas, kidney, testes, lung, heart, brain, eye, thyroid, and prostate. be important are future studies examining the regulation of WASP message and synthesis of the protein.
THE WAS: A CYTOSKELETAL DISEASE?
The disparate phenomenology exhibited by WAS blood cells can be unified within the framework of the hypothesis that the WAS belongs to the group of diseases that arise from inherited mutations of a component of a cytoskeletalsurface membrane complex ("cytoskeletal diseases"). Such mutations lead to multistep pathologic changes as seen in hereditary spherocytosis, hereditary elliptocytosis, and Duchenne muscular dystrophy. The common cytopathologies in "cytoskeletal diseases" are (1) abnormalities of surface glycoproteins particularly sialomucins, (2) defects at the level of cell structure, and (3) destruction and loss of affected cells often with involvement of proteases.
In general, inherited mutations of one component of a cytoskeletal-membrane complex lead to absencefloss of other associated components. For example, in hereditary elliptocytosis, there are mutations of a-spectrin or P-spectrin or glycophorin C or protein 4.1, and these cause abnormalities of the erythrocyte complex consisting of the cytoskeletal components spectrin, ankyrin, protein 4.1, and the surface membrane components band 3 and glycophorin C." Similarly, in hereditary spherocytosis, mutations of P-spectrin or ankyrin or protein 4.2 or band 3 cause different abnormalities of this complex. The abnormal cytoskeletal-membrane complex in spherocytosis leads to uncoupling of the lipid bilayer from the cytoskeleton and to osmotic fragility. Spherocytosis, the hallmark of the disease, results from the reduction of cell surface area due to loss of membrane in the form of microvesicles. An important feature shared by hereditary spherocytosis and hereditary elliptocytosis is increased erythrocyte destruction; various parameters are improved but not normalized by splenectomy.
Another "cytoskeletal disease," Duchenne muscular dystrophy (DMD), results from mutations in dystrophin. In normal muscle cells, a multi-subunit cytoskeletal-membrane complex is assembled, which includes the cytoskeletal protein dystrophin. In DMD muscle cells, the complex is assembled, but over time and because of the absence of dystrophin, the surface membrane components are lost as an early step of the pathologic muscle cell destructive process that may involve enhanced Ca2'-dependent p r o t e o l y s i~.~~-~~ We hypothesize that a counterpart process occurs in WAS blood cells, ie, that absenceldefects of WASP cause cytoskeletal structures to be aberranthnstable, which causes restricted use only.
For personal at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From functional defects, and with time in the circulation leads to loss of surface sialoglycoproteins, protease activation in platelets (described below), and shortened survival of circulating platelets and nonactivated T lymphocytes.
In considering the defective/absent WASP molecule in Wiskott-Aldrich blood cells within the framework of "cytoskeletal diseases," it should be noted that "cytoskeletallike diseases" can also arise due to mutations of molecules, which are not themselves part of the cytoskeletal-membrane complex, but which affect the complex. Examples include the anemia component (erythrocyte degradation) of P-thalassemia and sickle cell anemia in which inherited defects of hemoglobin lead via defective cytoskeletodcytoarchitecture to defects of the surface sialoglycoprotein glycophorin and premature destructiofloss of circulating erythrocytes. CD43 defects: Implications for cell survival. Defects of CD43 have been detected also in another T-cell immunodeficiency, human immunodeficiency virus type 1 (HIV-I) infection. The evidence is the CD43 autoantibodies specifically found in sera of early HIV-1-infected patients.86 HIV-1 infection of T-lymphoid cells in vitro causes CD43 to be hyposial~lated,~~ which may lead to degradation in vivo because desialylation substantially increases protease-sensitivity of CD43." Sialylation levels have not been examined in WAS cells, but enhanced susceptibility of CD43 to degradation was indicated by overnight storage of whole blood under defined conditions, which caused dramatic loss of CD43 From WAS T lymphocytes but not from normal T lymphocytes.8') tected3D.80-82 as well as deficient surface expression of CD23 Structurally, CD43 and GPIb have extracellular regions rich in serine, threonine, and proline that carry a high density of sialylated 0-glycans ("surface mucins")" and these regions, because of steric interactions and extensive hydration, are expanded, linear, and rigid." CD43 extends 4.5 nm from the phospholipid bilayer, dwarfing and masking other surface molecules92 and contributing substantially to the leukocyte g l y c o~a l i x .~~ These findings at least partially explain the in vitro action of CD43 as an anti-adhesion molecule demonstrated by transfection of HeLa cells94 and by gene deletion in a T-cell liney5 and the putative in vivo protective effect of CD43 in regulating survival of circulating leukocyte^.^^^^^
The loss of T-lymphocyte CD43 in the WAS (and in HIV-1 infection) may predispose the cells to adhesion reactions, activation reactions, and/or premature loss from the circulation. CD43 may also be vital in delivering a costimulatory signal to T lymphocytesy5a (early studies reviewed in ref 45).
Defects of lymphoid cell microvilli. Scanning electron microscopy showed morphologic defects in WAS lymphocytes. Whereas normal nonactivated blood lymphocytes are covered with slender microvillous projections, WAS blood lymphocytes are relatively devoid of microvilli and are also qualitatively abnormal with short blunted microvilli9" (Fig  2) . The cytoarchitectural defect, unlike other defects in WAS T lymphocytes, is consistently present even in newborns with WAS, suggesting that it is a (nearly) direct result of the absence/defects of WASP.
An important study by Yonemura et aly7 determined that the microvilli of rat leukemia cells bear displays of CD43 molecules. In human T cells, CD43 is also selectively expressed on the microvilli as demonstrated by high-resolution scanning immunoelectron microscopy of CEM cells (Remold-O'Donnell and Erlandsen, study in progress). Figure  3 shows the selective localization of CD43 as dense clusters of bright gold particles covering the slender surface projections.
The selective expression of the innately anti-adhesive CD43 molecule at the most accessible sites on circulating blood cells is consistent with its putative role as protective molecule. Indeed, the regulatory role of blood cell microvilli has been increasingly recognized based on studies of leukocyte adhesion interactions under conditions of flow. To the extent examined, the initially acting surface molecules responsible for engagement of circulating leukocytes are also selectively expressed on microvilli, for example, L-selectin, PSGL-I , and the integrin a4P7, each responsible for "tethering" blood cells to specific endothelial wall counterreceptors.y8""' The presentation on microvilli of both the anti-adhesion molecule CD43 and the early acting adhesion molecules indicates the importance of microvilli in determining the fate of circulating leukocytes.
The topographical colocalization in T-lymphoid cells of microvilli and CD43, two components that become defective in WAS patient T cells, suggests that the inherited defects or absence of WASP in this disease affect the stability of microvilli and/or the anchoring or presentation of surface molecules. Studies of rat thymocytes describe cytoplasmic components that colocalize with the microvilli, which may play a role in linking the specialized surface membrane glyuse only. coproteins of these structures to the cytoskeleton. Fluorescence microscopy showed a minor subset of actin filaments in the peripheral cell region underlying the microvillous processes and also identified ezrin/radixin/moesin ( "ERM").''7 The latter are a family of not easily distinguished cytoskeletal proteins containing actin-binding domains and membrane-binding A functional role for ezrin/ radixinhoesin in generating or maintaining surface protrusions was suggested by the finding that microvilli, filapodia, and ruffles disappear from the surface of thymoma cells treated with antisense oligonucleotides against these proteins." During mitosis, the microvilli and ezrinhadixinl moesin are redistributed, becoming colocalized at the contractile ring in association with newly formed actin structure~,'~ suggesting a role also in cell division.
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Abnormalities in protease calpain. WAS patient platelets were examined for content of calpain (Ca"-dependent neutral protease), the ubiquitous and relatively specific protease that cleaves cytoskeletal proteins and functions in cytoskeletal reorganization reactions, eg, secretion'"'; this enzyme is found in the cytoplasm as the inactive precursor procalpain.'" Procalpain levels are particularly high in platelet~."'~ When cytoplasmic Ca" levels are increased, procalpain undergoes autoactivation'"' and active calpain is released from normal platelets in some circumstances as part of the microvesiculation process.'"'' Although platelets from immune thrombocytopenia patients had normal levels of calpain, the calpain activity of platelets of seven WAS patients was decreased to 59% 2 4% ( P < .01) relative to normal platelets."" In these comparisons, WAS and normal platelets are equalized for cytosolic volume. The antigenic p-calpain content of platelets of nine WAS patients was similarly decreased to 58% 2 14% relative to paired normals. Addition of ionophore and CaZ+ caused p-procalpain to be rapidly (0.5 minutes) and quantitatively converted to active p-calpain, which was rapidly degraded in both WAS and normal platelets.
The combined findings of decreased procalpain levels in WAS platelets and a normal activation/degradation process suggest that procalpain depletion is the result of its aberrant activation, possibly due to defective regulation of Ca". In contrast to the platelet findings, antigenic p-calpain levels were normal in WAS patients' lymphocytes,'"' and thus abnormal procalpain activation/depletion in the WAS is exclusive or more pronounced in platelets.
Destructive thrombocytopenia. Abnormalities of calpain occur also in autosomally inherited Montreal platelet syndrome, characterized by large platelets,"' and in thrombotic thrombocytopenic purpura, in which active platelet calpain bound to microvesicles is released into plasma.'" The common feature of the WAS and these thrombocytopenias is the use only.
For personal at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From dominant role of platelet destruction. These findings suggest that aberrant activation of procalpain in circulating WAS platelets plays a role in generating the severe thrombocytopenia and small platelet size characteristic of this disease.
When sonicated normal platelets were used in vitro to simulate conditions associated with massive destruction of WAS platelets, platelet calpain, which was previously known to cleave platelet GPIb, also selectively cleaved CD43 on the surface of desialylated T lymphocyte^."^ Thus, platelet calpain, in conjunction with hyposialylation, may contribute to CD43 loss from WAS T lymphocytes.
CELL LINE MODEL OF THE WAS
The effects of progressive disease limit the utility of patient cells as an experimental system to study cellular defects in WAS. Patient primary blood lymphocytes, because of infections, are subject to fluctuation in subpopulation and activation status. In addition, there is no a priori criterion to determine whether a phenomenological defect in patient blood cells, eg, CD43 deficiency or paucity of microvilli, is the direct result of the absence or defect of WASP ("intrinsic defect"), or is the result of secondary changes that occur when the defective cells circulate. With the aim of a more nearly ideal model of the disease, a panel of polyclonal IL-2-dependent long-term T-cell lines was generated by allogeneic stimulation of blood lymphocytes of WAS patients and normal individuals. Surface molecules, quantified by flow cytometry, are not different in patient and normal cell lines and are appropriate for cells of T-lymphocyte origin.'I4 The WAS patient T-cell lines recapitulate two important characteristics of the disease: restricted responsiveness and defective cytoarchitecture (described below). On the other hand, the levels and molecular mass of CD43 are normal, strongly indicating that the CD43 deficiency of WAS blood lymphocytes results from events occurring in the patient circulation."'
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Deficient responsiveness in WAS T-cell lines.
The WAS T-cell lines have normal proliferative response to allogeneic stimulation and to mitogens, indicating that the specificity and mechanism for cell proliferation is intact. In contrast, proliferative response to immobilized anti-CD3 antibodies is absent or substantially reduced in the WAS patient cell lines relative to normal lines (Fig 4) .
The restricted nonresponsiveness of the WAS T-cell lines was detected also at an earlier stage as decreased production of L -2 in response to immobilized anti-CD3'I4; the binding of (soluble) CD3 antibody was normal. This striking and restricted in vitro deficiency of the WAS T-cell lines parallels the selective in vivo deficient response of WAS cells to polysaccharide antigens. Both situations may reflect the inability of WAS lymphoid cells with a flawed cytoskeleton to process stimulation signals when challenged with large inflexible polymeric structures.
Structural defects in WAS T-cell lines. Scanning electron microscopy showed a dense display of surface microvilli on the normal T-cell lines, but microvilli were substantially diminished in number and size on the WAS T-cell lines."' The expression of this defect by the patient cell lines strongly indicates that defective cytoarchitecture is a direct or nearly direct reflection of the absence/defects of the primary gene product WASP.
Transmission electron microscopy-showed significant differences in overall morphology and in cytoskeleton composition and structure. Whereas normal T-cells are mostly round with surfaces replete with microvillous projections, WAS T cells are heterogeneous with many having elongated or irregular shapes and smooth surfaces lacking microvilli. Cells in the process of dividing are much more numerous in WAS lines, suggesting a subtle functional defect in cell division.
To examine cytoskeletal structure, the T cells were fixed by a method that preserves actin microfilaments and reduces use only.
For the complexity of the cytoplasm."" Actin filaments (7 nm) in normal T-cell lines form a network that is mostly concentrated at the cell periphery from which they extend into villous projections (Fig SA) . In WAS T cells the peripheral actin network is poorly delineated (Fig SB) . It is likely that the disruptedpoorly developed submembranous actin network plays a role in the defective cytoarchitecture and lack of microvilli that characterize WAS T cells.
CONCLUSIONS AND FUTURE DIRECTIONS
Thus. the postulate that the WAS is a "cytoskeletal disease," although by no means proven, rests on overlapping areas of evidence. According to the postulate, absence or defects of WASP leads to abnormalities of assembly, stability, or function at the level of the cell cytoskeleton of patient T lymphocytes and platelets. Supportive findings include the multiplicity of secondary abnormalities generated in circulating WAS cells, particularly the alteration of surface antigens, as well as the enhanced susceptibility for activation of the protease calpain in WAS platelets and the apparent degradation by proteolysis of surface sialoglycoproteins. Also important are the paucity of microvilli and, as shown above, the structural defects in the WAS patient T-cell lines. It will be important to determine whether WAS platelets have counterpart abnormalities at the ultrastructural level. Consistent also is the finding that, as in other cytoskeletal diseases of blood cells such as hereditary spherocytosis and hereditary elliptocytosis, the spleen plays a major role in accentuating the WAS cellular defects.
Because of the discovery of WASP, the primary affected X chromosome product, some very discrete questions can now be addressed including determining why and how WASP expression is apparently restricted to hematopoietic cells and defining the biochemistry and principle functions of WASP. Questions that are particularly relevant within the context of WAS blood cells include: What does WASP interact with in resting blood cells? Does WASP have a unique function in platelets and lymphocytes or is it also functionally important in other white blood cells'? What are the consequences for blood cells when WASP is deleted? How does the absence or defects of WASP in Wiskott-Aldrich blood cells cause structural defects. restricted responsiveness, and loss of circulating blood cells?
As a result of screening techniques developed in the studies of WASP m~t a t i o n s .~~.~'~~" and of sensitive methods for detecting nonrandom X-chromosome inactivation3'.J'.M as well as the newly detected polymorphisms that flank the WASP gene," the capability is dramatically improved for diagnosing patients with this rare and severe disease and for genetic counseling through detection of carriers in WAS families and prenatal diagnosis. Thus, the battle is half won. It is time to turn to the new challenge. which is to come to understand the mechanisms that generate defects at the level of the WAS patients' cells and that cause malfunction and loss of their platelets and T lymphocytes.
The identification of the nature and chronology of the pathologic events that occur in WAS blood cells will be important for understanding the disease and will be useful for monitoring anticipated new treatments such as gene therapy and possibly for devising therapeutic strategies for preventing the more severe manifestations of the disease. Knowledge of the molecular pathology of the WAS will likely contribute also to understanding of mechanisms that regulate function and life span of T lymphocytes and platelets in normal individuals and their disregulation in other immunodeficiencies and destructive thrombocytopenias.
NOTE ADDED IN PROOF
Several recent studies have begun the molecular description of WASP interactions with known cellular proteins. WASP has been shown to bind to ~47"'~, an SH3-containing use only. 
